SCHEMBL343400

SCHEMBL343400

Cc1ccc2cc[nH]c2n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.57
ADORA1 P30542 1/20 0.57
AXL P30530 3/20 0.45
NUDT1 P36639 1/20 0.45
CCR1 P32246 1/20 0.44
RAB9A P51151 1/20 0.44
CCR5 P51681 1/20 0.44
BRD4 O60885 1/20 0.42
CYP1A2 P05177 3/20 0.38
BRAF P15056 1/20 0.37
APP P05067 1/20 0.37
KDM4E B2RXH2 3/20 0.35
KMT2A Q03164 2/20 0.35
PRKCI P41743 1/20 0.34
METAP2 P50579 1/20 0.33
CDK8 P49336 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
CASP6 P55212 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29497464 1.00 ADORA2A (0.57) ADORA2AADORA1AXLNUDT1CCR1
SCHEMBL12205185 0.73 NCF1 (0.47) ADORA2AADORA1AXLNUDT1BRD4
SCHEMBL8039008 0.73 ADORA1 (1.00) ADORA2AADORA1KDM4EKMT2A
SCHEMBL414134 0.71 MAPK1 (0.45) ADORA2AADORA1AXLNUDT1BRD4
SCHEMBL963531 0.71 AXL (0.45) AXLNUDT1BRD4APPKDM4E
SCHEMBL4063067 0.71 AXL (0.45) ADORA2AADORA1AXLNUDT1BRD4
SCHEMBL684703 0.71 AXL (0.45) AXLNUDT1BRD4APPCDK8
SCHEMBL1334813 0.71 AXL (0.45) ADORA2AADORA1AXLNUDT1BRD4
SCHEMBL12798351 0.71 AXL (0.45) ADORA2AADORA1AXLNUDT1BRD4
SCHEMBL31276718 0.71 AXL (0.45) AXLNUDT1BRD4APPKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7374882-B2 Method for base sequencing and biologically active nucleic acids RIKEN (JP) 2008-05-20 US claimed
EP-1641942-A2 COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME Applera Corporation (US) 2006-04-05 EP claimed
US-20050053979-A1 Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same APPLIED BIOSYSTEMS, LLC 2005-03-10 US claimed
WO-2004111072-A2 COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME APPLERA CORPORATION (US) 2004-12-23 WO claimed
US-20040115665-A1 Method for base sequencing and biologically active nucleic acids RIKEN (JP) 2004-06-17 US claimed
JP-2004514440-A 2004-05-20 JP claimed
EP-1348035-A2 METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS Riken (JP) 2003-10-01 EP claimed
WO-2002044195-A2 METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS RIKEN (JP) 2002-06-06 WO claimed
EP-4744661-A2 NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2026-05-20 EP disclosed
EP-4719437-A1 CONNECTOR MODIFIED SYNTHETIC RIG-I AGONISTS AND METHODS OF USING THE SAME RIGImmune Inc. (US) 2026-04-08 EP disclosed
EP-4298092-B1 NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2025-11-26 EP disclosed
US-12448368-B2 Indole compounds as androgen receptor modulators NIDO BIOSCIENCES, INC. (US) 2025-10-21 US disclosed
US-20250230157-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS RAPPORT THERAPEUTICS, INC. 2025-07-17 US disclosed
WO-2025111547-A1 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF RGENTA THERAPEUTICS, INC. (US) 2025-05-30 WO disclosed
US-20050053979-A1 Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same APPLIED BIOSYSTEMS, LLC 2005-03-10 US disclosed
WO-2004111072-A2 COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME APPLERA CORPORATION (US) 2004-12-23 WO disclosed
US-20040115665-A1 Method for base sequencing and biologically active nucleic acids RIKEN (JP) 2004-06-17 US disclosed
EP-1348035-A2 METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS Riken (JP) 2003-10-01 EP disclosed
WO-2002044195-A2 METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS RIKEN (JP) 2002-06-06 WO disclosed
WO-1996032391-A1 PROCESS FOR PREPARING AZAINDOLES WITH AN ACTIVATED COPPER CHROMITE CATALYST BY CATALYTIC DEHYDROCYCLISATION OF ALKYLPYRIDYLAMINES (PYRIDOPYRIDINES) LONZA AG (CH) 1996-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050053979-A1 Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same DTYMK, UNG, TPR ADORA2A 2400/4885ADORA1 2807/4885AXL 622/4885
US-12448368-B2 Indole compounds as androgen receptor modulators AR, FSHR, ADRB3 ADORA2A 289/4885ADORA1 537/4885AXL 3932/4885
US-20250230157-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN1, GRIN2B, GRIN3A ADORA2A 127/4885ADORA1 104/4885AXL 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.